Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GA, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clement K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023 Jan 16;18(1):12. doi: 10.1186/s13023-022-02602-4

Spira A, Zhou X, Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A, Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2). Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.

Spira A, Liao L, Zhou X, Gnanasakthy A, Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2). Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.

Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001

Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022 Feb 5;17(1):38. doi: 10.1186/s13023-022-02186-z

Forsythe E, Haws RM, Argente J, Beales P, Chirila C, Clement K, Dollfus H, Martos-Moreno GA, Gnanasakthy A, Buckley BC, Mallya U, Haqq AM. Quality of life in patients with bardet-biedl syndrome in a setmelanotide phase 3 trial. Poster presented at the 2021 Obesity Week Virtual Conference; November 1, 2021.

Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life in POMC or LEPR deficiency: setmelanotide phase 3 trials. Poster presented at the 2021 Virtual Overcoming Obesity Conference; October 14, 2021.

Chirila C, Odom D, Gnanasakthy A. Patient-reported outcomes assessment scheduling in oncology: are we introducing potential bias? Presented at the 2021 DIA Virtual Annual Meeting; June 27, 2021.

Spira AI, Chen L, Zhou X, Gnanasakthy A, Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma. Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos MA. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial. Eur J Haematol. 2020 May;104(5):443-58. doi: 10.1111/ejh.13379.

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.

Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.

Zhou X, Garbinsky D, Gnanasakthy A. Methods for reporting the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2019 Duke Industry Statistics Symposium (DISS); April 11, 2019. Durham, NC. Previously presented at the ISPOR 23rd Annual International Meeting.

Zhou X, Eid D, Gnanasakthy A. Methods for reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S226. doi: 10.1016/j.jval.2018.04.1528

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043